Dapagliflozin Patient Satisfaction Survey

AstraZeneca

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Study type: Observational

Funder types: Industry

Identifiers

NCT02805283

D1690R00026

Details and patient eligibility

About

The purpose of this study is to evaluate the diabetes related treatment satisfaction for patients with type 2 diabetes mellitus

Full description

This is a cross-sectional, observational patient survey study. Study subjects will be adult commercial members of the large US health plan affiliated with Optum with evidence of T2D initiating dapagliflozin or a sulfonylurea medication within the 3 months prior to survey mailing.

Enrollment: 653 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least one pharmacy claim for dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for an SGLT2 medication during the 6 months prior to sample identification.
• Evidence of T2D diagnosis.
• Age ≥18 as of the drug index date.
• 6 months of continuous enrollment in a commercial health plan with both pharmacy and medical benefits during the identification period through the patient interview sample identification date.
• Self-reported T2D diagnosis during the patient interview.

Exclusion criteria

• Patients with evidence of type 1 diabetes mellitus and unknown type
• Patients who are pregnant

Trial design

653 participants in 2 patient groups

Dapagliflozin, dapagliflozin/met ER

Description:

Dapagliflozin cohort have at least one pharmacy claim for either dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.

Sulfonylurea

Description:

Sulfonylurea cohort have at least one pharmacy claim for sulfonylurea in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.